Breast Cancer :: Anastrozole – Arimidex – New drug for breast cancer
A drug shown to be more effective than the previous “gold standard” treatment for early-stage breast cancer sufferers becomes available to patients.
Drug
Smallpox :: Cancer Drug Slows Poxvirus in Mice
Mice given a relatively new cancer drug can survive an otherwise lethal dose of vaccinia virus, a relative of smallpox virus, report scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
HIV :: First Generic Nevirapine for AIDS Relief
The Food and Drug Administration (FDA) announced the tentative approval of two applications for nevirapine tablets manufactured by Ranbaxy Laboratories Limited, Guragon, India and Aurobindo Pharma Limited, Hyderabad, India. These are the first generic versions of Viramune Tablets manufactured by Boehringer Ingelheim. These products will now be available for consideration for purchase under the President?s Emergency Plan for AIDS Relief (PEPFAR).
HIV :: Efavirenz for AIDS Relief
The Food and Drug Administration (FDA) within the U.S. Department of Health and Human Services (HHS) announced the tentative approval of efavirenz tablets manufactured by Aurobindo Pharma LTD. of Hyderabad, India. This product is the first tentatively approved generic version of Sustiva Tablets (manufactured by Bristol-Myers Squibb). Efavirnez will now be available for consideration for purchase under the President’s Emergency Plan for AIDS Relief (PEPFAR).
Heart Disease :: BiDil Heart Failure Drug for Black Patients
The Food and Drug Administration (FDA) approved BiDil (bye-DILL), a drug for the treatment of heart failure in self-identified black patients, representing a step toward the promise of personalized medicine.
HIV :: Aptivus – New Therapy for HIV Patients with Advanced Disease
The Food and Drug Administration (FDA) announced the approval of Aptivus (tipranavir) capsules, an HIV protease inhibitor, to be given with ritonavir for treatment of HIV-1 infected adults. This is the second drug approved for patients with advanced HIV disease, and provides a new therapy for patients with limited treatment options.
Health Education :: A new style of public health education
Starting in West Philadelphia, a program will use hair salons as a venue to teach women about diabetes and asthma.
Joint Pain :: New Topical Therapy Brings Relief to Pain Sufferers
ALCiS Health Inc., a consumer health company specializing in pain relief and body therapy products that utilize unique drug delivery technologies, announced the availability of ALCiS Daily Relief, a topical pain cream engineered to provide fast relief from muscle and joint pain, including that associated with arthritis, backache, strains, sprains and bruises.
Bipolar Disorder :: Mri Shows Up Brain Differences in Bipolar Disorder
Efforts to define the abnormally activated areas in the brains of people with bipolar disorder could lead to new drug treatments and better coping strategies, investigators reported at the International Conference on Bipolar Disorder in Pittsburgh.
Tuberculosis :: Promising New TB Drug Enters Clinical Trial
A promising new drug candidate that may be effective against both actively dividing and slow-growing Mycobacterium tuberculosis (M. tb) has begun testing in humans, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, announced today. The novel antibiotic, PA-824, may shorten the time needed to treat tuberculosis (TB), a contagious disease that claims approximately two million lives worldwide each year. In partnership with the non-profit New York-based Global Alliance for TB Drug Development (TB Alliance), NIAID contributed to the drug candidate?s preclinical safety and efficacy testing in animal models. Now, a clinical trial to assess PA-824?s safety, sponsored by the TB Alliance, has opened at a medical clinic in Lincoln, NE.